Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 3/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | GRN | P28799 | 1/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23964453 | 0.80 | GAA (0.48) | GAAMGLLNR1H3FAAH | |
| SCHEMBL1754328 | 0.73 | AOC2 (0.51) | GAAMGLLNR1H3L3MBTL1 | |
| SCHEMBL23352579 | 0.71 | GAA (0.43) | GAAMGLLNR1H3PARP1 | |
| SCHEMBL8349954 | 0.70 | PRMT6 (0.59) | GAAL3MBTL1MEN1KMT2A | |
| SCHEMBL4404334 | 0.70 | LMNA (0.53) | MEN1KMT2A | |
| SCHEMBL12666620 | 0.70 | ALDH1A1 (0.54) | GAAL3MBTL1MEN1KMT2APARP1 | |
| SCHEMBL758533 | 0.69 | ACHE (0.55) | MEN1KMT2A | |
| SCHEMBL29941639 | 0.69 | ACHE (0.55) | MEN1KMT2A | |
| SCHEMBL10190904 | 0.69 | PRMT6 (0.62) | GAAL3MBTL1MEN1KMT2A | |
| SCHEMBL12775844 | 0.69 | MPO (0.48) | GAAL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | ASCENDIS PHARMA A/S (DK) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | CD44, HPSE, MMP13 | GAA 293/4885MGLL 2325/4885NR1H3 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.